Predicted protein targets (top 12)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA12 | O43570 | 3/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 3/20 | 0.36 |
| ▸ | CA1 | P00915 | 2/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | BRS3 | P32247 | 1/20 | 0.35 |
| ▸ | RORC | P51449 | 3/20 | 0.35 |
| ▸ | SCN9A | Q15858 | 6/20 | 0.34 |
| ▸ | CA2 | P00918 | 2/20 | 0.34 |
| ▸ | BDKRB1 | P46663 | 2/20 | 0.34 |
| ▸ | EPAS1 | Q99814 | 1/20 | 0.33 |
| ▸ | NPY5R | Q15761 | 2/20 | 0.33 |
| ▸ | ACHE | P22303 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL16290323 | 0.88 | CA12 (0.35) | CA12CA14CA1CA7BRS3 | |
| SCHEMBL16290506 | 0.82 | BDKRB1 (0.45) | CA12CA14CA1CA7BRS3 | |
| SCHEMBL18710390 | 0.80 | SCN9A (0.35) | RORCSCN9ABDKRB1 | |
| SCHEMBL16290470 | 0.79 | CA12 (0.34) | CA12CA14CA1CA7BRS3 | |
| SCHEMBL16290446 | 0.76 | CA12 (0.40) | CA12CA14CA1CA7BRS3 | |
| SCHEMBL16290457 | 0.75 | EPAS1 (0.37) | CA12CA14CA1CA7BRS3 | |
| SCHEMBL16290324 | 0.75 | CA1 (0.47) | CA12CA14CA1CA7CA2 | |
| SCHEMBL16290391 | 0.75 | STS (0.42) | CA12CA14CA1CA7BRS3 | |
| SCHEMBL17040899 | 0.73 | BDKRB1 (0.44) | SCN9ABDKRB1EPAS1 | |
| SCHEMBL19951733 | 0.72 | RIPK1 (0.36) | CA12CA14CA1CA7CA2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 10 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2865663-B1 | NOVEL INDANESULFAMIDE DERIVATIVE | EISAI R&D MAN CO LTD (JP) | 2017-04-05 | — | — | EP | disclosed |
| EP-2865663-B1 | NOVEL INDANESULFAMIDE DERIVATIVE | EISAI R&D MAN CO LTD (JP) | 2017-04-05 | — | — | EP | disclosed |
| EP-2865663-A1 | NOVEL INDANESULFAMIDE DERIVATIVE | Eisai R&D Management Co., Ltd. (JP) | 2015-04-29 | — | — | EP | disclosed |
| EP-2865663-A1 | NOVEL INDANESULFAMIDE DERIVATIVE | Eisai R&D Management Co., Ltd. (JP) | 2015-04-29 | — | — | EP | disclosed |
| US-9018260-B2 | Indanesulfamide derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-04-28 | — | — | US | disclosed |
| US-9018260-B2 | Indanesulfamide derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-04-28 | — | — | US | disclosed |
| US-9018260-B2 | Indanesulfamide derivatives | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2015-04-28 | — | — | US | disclosed |
| US-20140371319-A1 | NOVEL INDANESULFAMlDE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2014-12-18 | — | — | US | disclosed |
| US-20140371319-A1 | NOVEL INDANESULFAMlDE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2014-12-18 | — | — | US | disclosed |
| US-20140371319-A1 | NOVEL INDANESULFAMlDE DERIVATIVES | EISAI R&D MANAGEMENT CO., LTD. (JP) | 2014-12-18 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140371319-A1 | NOVEL INDANESULFAMlDE DERIVATIVES | SCN1A, SCN7A, SCN2A | CA12 2022/4885CA14 2800/4885CA1 219/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.